Skip to main
XFOR
XFOR logo

XFOR Stock Forecast & Price Target

XFOR Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

X4 Pharmaceuticals Inc. demonstrates a positive financial outlook, projecting total revenues to reach $6.1 million in 2025 and escalating to $251 million by 2031, indicating significant long-term growth potential. The exclusive licensing agreement with Norgine Pharmaceuticals, covering Europe, Australia, and New Zealand, is expected to contribute escalating double-digit royalties, further enhancing revenue streams. Despite current market adoption challenges for mavorixafor, the international expansion and strategic management measures are viewed as prudent steps toward maximizing long-term profitability and geographic reach.

Bears say

X4 Pharmaceuticals's outlook is negatively impacted by several factors, including a strategic restructuring that entails a 30% reduction in workforce and an anticipated annual spending decrease of $30-$35 million. Furthermore, the company has revised its revenue projections for Xolremdi downward for 2025 due to changes in their commercial strategy, indicating potential challenges in generating expected revenue. Additionally, critical delays in market entry for its therapies, including WHIM syndrome and CN in both the US and EU, extend timelines significantly, contributing to concerns about the company's growth prospects and operational efficiency.

XFOR has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of X4 Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About X4 Pharmaceuticals Inc (XFOR) Forecast

Analysts have given XFOR a Buy based on their latest research and market trends.

According to 10 analysts, XFOR has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

X4 Pharmaceuticals Inc (XFOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.